title: Exercise tolerance in patients with heart failure--how should it be measured?
abstract: The exercise capability of 12 patients with heart failure was investigated by a variety of different methods before and after treatment with the vasodilator flosequinan. Two treadmill protocols were used, a modified Bruce with incremental workloads and a fixed workload protocol. On placebo, mean exercise time was greater with the Bruce protocol, 526 (64) s, than with the fixed protocol, 359 (59) s, P less than 0.005. Flosequinan increased exercise time more with the fixed protocol, so after 5 weeks' treatment exercise time was the same with both protocols; 680 (64) s with the Bruce and 673 (147) s with the fixed protocol. When the results are expressed as work, the patients achieved less with the Bruce protocol, 7.8 (1.9) kJ, than with the fixed protocol 12.5 (1.5) kJ on placebo, P less than 0.01. After flosequinan, the respective values were 14.5 (2.8) and 25.3 (5.1) kJ. Flosequinan improved corridor walk test times but there was no relationship between this and either treadmill test. Pedometer scores of customary activity were unchanged by flosequinan and were not correlated with any other exercise test. Different methods of assessing exercise capability provide different measures of patients' incapacity.
authors.affiliation: Department of Medicine, University Hospital, Nottingham, England.
authors.forename: A J
authors.initials: AJ
authors.lastname: Cowley
authors.forename: L
authors.initials: L
authors.lastname: Fullwood
authors.forename: K
authors.initials: K
authors.lastname: Stainer
authors.forename: J R
authors.initials: JR
authors.lastname: Hampton
mesh_terms: D002985:Clinical Protocols; D005080:Exercise Test / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D010101:Oxygen Consumption; D011804:Quinolines / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan